NanoViricides, Inc. (NYSE American: NNVC) announced that a Phase II clinical trial of its antiviral candidate NV-387 for the treatment of MPox is expected to begin soon in the Democratic Republic of Congo, with site preparation and staff training scheduled for early April 2026. The study, already approved by the DRC regulatory agency, will evaluate the safety and effectiveness of NV-387 against Clade I MPox, as the company advances regulatory development and seeks Orphan Drug Designation from the U.S. FDA. This trial is particularly significant because Clade I MPox is associated with higher morbidity and mortality compared to the Clade II strain that caused the global 2022 outbreak. As the DRC continues to report rising cases, an effective treatment could be critical for outbreak containment.
The trial marks a major step for NanoViricides, which has focused on developing nanomaterial-based antiviral therapies. NV-387 is a broad-spectrum antiviral drug candidate that the company plans to develop for multiple indications, including respiratory syncytial virus, COVID-19, influenza, and other respiratory viral infections, in addition to MPox/smallpox. The drug is designed using the company's proprietary nanoviricide technology, which aims to encapsulate and neutralize viruses. Unlike traditional small-molecule drugs, NV-387 is a polymeric micelle that can be loaded with antiviral agents or used alone. The company has also developed NV-CoV-2, a version without remdesivir, and NV-CoV-2-R, which encapsulates remdesivir.
The initiation of this Phase II trial is important for several reasons. First, it addresses an urgent public health need. The World Health Organization has declared MPox a Public Health Emergency of International Concern, and treatments beyond supportive care are limited. Currently, tecovirimat (TPOXX) is the primary antiviral used, but its efficacy against Clade I has been questioned, and resistance has been reported. NV-387 offers a novel mechanism of action, potentially providing an alternative for patients who do not respond to existing therapies. Second, the trial supports NanoViricides' regulatory strategy. By seeking Orphan Drug Designation from the FDA, the company could gain incentives such as tax credits, fee waivers, and seven-year market exclusivity upon approval, which would enhance the drug's commercial potential.
The company's focus on MPox is part of a broader pipeline that includes candidates for HIV, hepatitis, herpes, influenza, dengue, and Ebola. NanoViricides holds a worldwide exclusive perpetual license to TheraCour's nanomedicine technology for several viral diseases. However, the company acknowledges the inherent risks of drug development, noting that lengthy timelines and substantial capital are required, and there is no assurance that any candidate will prove safe and effective in humans. The Phase II trial in the DRC will enroll patients with confirmed MPox and monitor viral load reduction, clinical improvement, and safety. Results are expected to inform further development and potential emergency use authorizations.
For more information, see the full press release at https://ibn.fm/4Ckhk and the company's newsroom at https://ibn.fm/NNVC.
